Cat. #151891
T47D-182R-1 Cell Line
Cat. #: 151891
Sub-type: Continuous
Unit size: 1x10^6 cells / vial
Organism: Human
Tissue: Breast
Disease: Cancer
Model: Cancer cell line
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Anne Lykkesfeldt
Institute: Danish Cancer Society
Primary Citation: Kirkegaard et al. 2014. Cancer Lett. 344(1):90-100. PMID: 24513268.
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: T47D-182R-1 Cell Line
- Cancer: Breast cancer
- Cancers detailed: Breast carcinoma;Fulvestrant resistant
- Research fields: Cancer;Drug development
- Tool sub type: Continuous
- Parental cell: T47D/S5
- Organism: Human
- Tissue: Breast
- Donor: Female, Caucasian, 54Y
- Disease: Cancer
- Growth properties: Adherent
- Model: Cancer cell line
- Description: T47D-182R-1 is an adherent human breast cancer cell line that exhibits resistance to fulvestrant (Faslodex). It was developed from the parental T47D/S5 cell line through long-term exposure to 100 nM fulvestrant. The cells retain an epithelial morphology. As resistance to fulvestrant—a common second-line endocrine therapy—is a clinical challenge, T47D-182R-1 represents a valuable model for studying acquired resistance mechanisms. It serves as a robust tool for identifying targeted therapies against resistant tumor cells, as well as for evaluating strategies to prevent or delay resistance emergence.
- Application: Determining molecular mechanisms around fulvestrant resistance
- Production details: Human breast cancer cell line derived from T47D/S5 by long term treatment with 100 nM fulvestrant.
- Biosafety level: 1
- Cellosaurus id: CVCL_1D34
Target Details
- Target: Oestrogen receptor
Applications
- Application: Determining molecular mechanisms around fulvestrant resistance
- Application notes: Oestrogen and progesterone receptor negative.
Handling
- Format: Frozen
- Passage number: Passage 166 (AL3372, AL3381)
- Growth medium: Phenol red free RPMI 1640 + 5% FCS + glutamax + 8ug Insulin/ml + 100 nM fulvestrant. Fetal Calf Serum (FCS) typically contains less estrogen than Fetal Bovine Serum (FBS) and is the preferred supplement for this cell line.
- Temperature: 37° C
- Atmosphere: 5% CO2
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
- Storage medium: 10% DMSO in FCS
- Subculture routine: Following thawing and counting, dilute the cell suspension with sufficient medium and distribute 5 mL each into T25 flasks to achieve a seeding density of 1.8 - 2.0 x 10^4 / cm2. Place in 37°C, 5% CO₂ incubator. Change medium after 24 hours to remove residual DMSO and then every 2-3 days. Subculture routine: Split 1:7 weekly (slow growing cell line) with Trypsin-EDTA for detachment at 37 °C for 5 minutes. Please also see detailed protocol within the Product Datasheet in the Documentation section below.
Related Tools
- Related tools: T47D/S5 Cell Line; T47D-182R2 Cell Line; Plasmax™ cell culture medium
References
- Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.
- Larsen et al. 2015. BMC Cancer. 15(1):1-15. PMID: 25885472.
- Kirkegaard et al. 2014. Cancer Lett. 344(1):90-100. PMID: 24513268.
